Cargando…

Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder

INTRODUCTION: As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated OBJECTIVES: Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero Guillena, S.L., De Burgos Berdud, I., Gálvez Medina, R., Serrano Rodriguez, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565178/
http://dx.doi.org/10.1192/j.eurpsy.2022.685
_version_ 1784808824395268096
author Romero Guillena, S.L.
De Burgos Berdud, I.
Gálvez Medina, R.
Serrano Rodriguez, E.
author_facet Romero Guillena, S.L.
De Burgos Berdud, I.
Gálvez Medina, R.
Serrano Rodriguez, E.
author_sort Romero Guillena, S.L.
collection PubMed
description INTRODUCTION: As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated OBJECTIVES: Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with a dual diagnosis of schizophrenia and substance use disorder Secondary: To compare the rate of fully vaccinated patients diagnosed with schizophrenia with and without a coexisting substance use disorder. METHODS: Retrospective descriptive study. The population in study is made up of patients with schizophrenia (46) and dual diagnosis schizophrenia (28) (following DSM 5 criteria) Confirmed cases were those cases with positive PCR RESULTS: There was not a stadistically significant difference in the prevalence of COVID 19 infection between both groups of patients. The prevalence of COVID infection among the dual diagnosis schizophrenia was 3.57% compared to 6.5% in those without coexisting substance abuse disorder. Relative to vaccination rate, we didn’t find a stadistically significant difference between both groups. However, there was a higher vaccination rate in the dual diagnosis schizophrenia group (82.12%) compared to the non-dual diagnosis schizophrenia group (69.56%) CONCLUSIONS: The prevalence of COVID 19 infection in the dual diagnosis schizophrenia cohort is 3.57% and in the group of patients with schizophrenia without substance abuse disorder is 6,5%. In those with dual diagnosis schizophrenia the vaccination rate was un 82.12%. It was 69.56% in those without coexisting substance abuse disorder. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9565178
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95651782022-10-17 Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder Romero Guillena, S.L. De Burgos Berdud, I. Gálvez Medina, R. Serrano Rodriguez, E. Eur Psychiatry Abstract INTRODUCTION: As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated OBJECTIVES: Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with a dual diagnosis of schizophrenia and substance use disorder Secondary: To compare the rate of fully vaccinated patients diagnosed with schizophrenia with and without a coexisting substance use disorder. METHODS: Retrospective descriptive study. The population in study is made up of patients with schizophrenia (46) and dual diagnosis schizophrenia (28) (following DSM 5 criteria) Confirmed cases were those cases with positive PCR RESULTS: There was not a stadistically significant difference in the prevalence of COVID 19 infection between both groups of patients. The prevalence of COVID infection among the dual diagnosis schizophrenia was 3.57% compared to 6.5% in those without coexisting substance abuse disorder. Relative to vaccination rate, we didn’t find a stadistically significant difference between both groups. However, there was a higher vaccination rate in the dual diagnosis schizophrenia group (82.12%) compared to the non-dual diagnosis schizophrenia group (69.56%) CONCLUSIONS: The prevalence of COVID 19 infection in the dual diagnosis schizophrenia cohort is 3.57% and in the group of patients with schizophrenia without substance abuse disorder is 6,5%. In those with dual diagnosis schizophrenia the vaccination rate was un 82.12%. It was 69.56% in those without coexisting substance abuse disorder. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9565178/ http://dx.doi.org/10.1192/j.eurpsy.2022.685 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Romero Guillena, S.L.
De Burgos Berdud, I.
Gálvez Medina, R.
Serrano Rodriguez, E.
Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
title Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
title_full Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
title_fullStr Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
title_full_unstemmed Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
title_short Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
title_sort prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565178/
http://dx.doi.org/10.1192/j.eurpsy.2022.685
work_keys_str_mv AT romeroguillenasl prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder
AT deburgosberdudi prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder
AT galvezmedinar prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder
AT serranorodrigueze prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder